Power-Hays, A; Dong, M; Punt, N; Mizuno, T; Smart, LR; Vinks, AA; Ware, RE. Rationale, Development, and Validation of HdxSim, a Clinical Decision Support Tool for Model-Informed Precision Dosing of Hydroxyurea for Children with Sickle Cell Anemia. Clinical Pharmacology and Therapeutics. 2024; 116:670-677.

Sadaf, A; Dong, M; Pfeiffer, A; Korpik, J; Kalfa, TA; Latham, T; Vinks, AA; Ware, RE; Quinn, CT. A pharmacokinetic-pharmacodynamic analysis of l-glutamine for the treatment of sickle cell disease: Implications for understanding the mechanism of action and evaluating response to therapy. British Journal of Haematology. 2024; 205:1147-1158.

Aygun, B; Lane, A; Smart, LR; Santos, B; Tshilolo, L; Williams, TN; Olupot-Olupot, P; Stuber, SE; Tomlinson, G; Latham, T; Ware, RE. Hydroxyurea dose optimisation for children with sickle cell anaemia in sub-Saharan Africa (REACH): extended follow-up of a multicentre, open-label, phase 1/2 trial. The Lancet Haematology. 2024; 11:e425-e435.

Costa, E; Isgrò, A; de Montalembert, M; Leufkens, HG M; Ware, RE; De Franceschi, L. Successes and pitfalls in orphan drug development for sickle cell disease. Blood Advances. 2024; 8:2455-2465.

Namazzi, R; Bond, C; Conroy, AL; Datta, D; Tagoola, A; Goings, MJ; Jang, JH; Ware, RE; Opoka, R; John, CC. Hydroxyurea reduces infections in children with sickle cell anemia in Uganda. Blood. 2024; 143:1425-1428.

Power-Hays, A; Tomlinson, GA; Tshilolo, L; Santos, B; Williams, TN; Olupot-Olupot, P; Smart, LR; Aygun, B; Lane, A; Stuber, SE; Latham, T; Ware, RE. Reducing transfusion utilization for children with sickle cell anemia in sub-Saharan Africa with hydroxyurea: Analysis from the phase I/II REACH trial. American Journal of Hematology. 2024; 99:625-632.

Sadaf, A; Dong, M; Pfeiffer, A; Latham, T; Kalfa, T; Vinks, AA; Ware, RE; Quinn, CT. A Population Pharmacokinetic Analysis of L-Glutamine Exposure in Patients with Sickle Cell Disease: Evaluation of Dose and Food Effects. Clinical Pharmacokinetics. 2024; 63:357-365.

Siegert, TF; Opoka, RO; Nakafeero, M; Carman, A; Mellencamp, KA; Latham, T; Hume, H; Lane, A; Ware, RE; Ssenkusu, JM; John, CC; Conroy, AL. Angiopoietin-2 is associated with sickle cell complications, including stroke risk, and decreases with hydroxyurea therapy. 2024; 1:100001.

Ware, RE; Quinn, CT. The bold promise of gene therapy for sickle cell disease. British Journal of Haematology. 2024; 204:381-382.

Shook, LM; Ware, RE. Screening for haemoglobin disorders: One size may not fit all. British Journal of Haematology. 2024; 204:26-28.

Smart, LR; Segbefia, CI; Latham, TS; Stuber, SE; Amissah-Arthur, KN; Dzefi-Tettey, K; Lane, AC; Dei-Adomakoh, YA; Ware, RE. Prospective identification of variables as outcomes for treatment (PIVOT): study protocol for a randomised, placebo-controlled trial of hydroxyurea for Ghanaian children and adults with haemoglobin SC disease. Trials. 2023; 24:603.

Teigen, D; Opoka, RO; Kasirye, P; Nabaggala, C; Hume, HA; Blomberg, B; John, CC; Ware, RE; Robberstad, B. Cost-Effectiveness of Hydroxyurea for Sickle Cell Anemia in a Low-Income African Setting: A Model-Based Evaluation of Two Dosing Regimens. Pharmacoeconomics Italian Research Articles. 2023; 41:1603-1615.

Rankine-Mullings, AE; Soares, D; Aldred, K; Chang-Lopez, S; Wisdom-Phipps, ME; Schultz, W; Latham, TS; Stuber, SE; Jackson, P; Ware, RE; Reid, ME. Hydroxyurea Improves Intelligence Quotient Scores in Children with Sickle Cell Anemia and Elevated Transcranial Doppler Velocity. Blood. 2023; 142:797.

McElhinney, K; Smart, LR; Howard, TA; Power-Hays, A; Ware, RE. A Novel, Rapid, and Accurate Quantitative Hydroxyurea Assay. Blood. 2023; 142:2530.

Sadaf, A; Dong, M; Korpik, J; Pfeiffer, A; Kalfa, TA; Latham, TS; Vinks, AA; Ware, RE; Quinn, CT. Effects of L-Glutamine on Biomarkers of Response in Sickle Cell Disease: A Pharmacokinetics-Pharmacodynamics Analysis. Blood. 2023; 142:1145.

Teoh, Z; Simpson, BN; Howard, T; McElhinney, K; Ware, R; Mena, R; Schlaudecker, EP. Codetection of Plasmodium falciparum in Children Hospitalized With Dengue Fever in the Dominican Republic. The Pediatric Infectious Disease Journal. 2023; 42:965-968.

Safeukui, I; Ware, RE; Mohandas, N; Haldar, K. Simultaneous adjunctive treatment of malaria and its coevolved genetic disorder sickle cell anemia. Blood Advances. 2023; 7:5970-5981.

Rankine-Mullings, A; Keenan, R; Chakravorty, S; Inusa, B; Telfer, P; Velangi, M; Ware, RE; Moss, JJ; Lloyd, AL; Edwards, S; Mulla, H. Efficacy, safety, and pharmacokinetics of a new, ready-to-use, liquid hydroxyurea in children with sickle cell anemia. Blood Advances. 2023; 7:4319-4322.

Piel, FB; Rees, DC; DeBaun, MR; Nnodu, O; Ranque, B; Thompson, AA; Ware, RE; Abboud, MR; Abraham, A; Ambrose, EE; Sung, L; Tshilolo, L; Wilkie, DJ; Ohene-Frempong, K. Defining global strategies to improve outcomes in sickle cell disease: a Lancet Haematology Commission. The Lancet Haematology. 2023; 10:e633-e686.

Ware, J; Mcelhinney, K; Latham, T; Lane, A; Dienger-Stambaugh, K; Hildeman, D; Spearman, P; Ware, RE. Sustained and Boosted Antibody Responses in Breast Milk After Maternal SARS-CoV-2 Vaccination. Breastfeeding Medicine. 2023; 18:612-620.

Namazzi, R; Opoka, R; Conroy, AL; Datta, D; Tagoola, A; Bond, C; Goings, MJ; Ryu, MS; Cusick, SE; Krebs, NF; Jang, JH; Tu, W; Ware, RE; John, CC. Zinc for infection prevention in children with sickle cell anemia: a randomized double-blind placebo-controlled trial. Blood Advances. 2023; 7:3023-3031.

Zhou, ZH; Cortese, MM; Fang, JL; Wood, R; Hummell, DS; Risma, KA; Norton, AE; KuKuruga, M; Kirshner, S; Rabin, RL; Forshee, R; Broder, KR; Anderson, S; Kozlowski, S. Evaluation of association of anti-PEG antibodies with anaphylaxis after mRNA COVID-19 vaccination. Vaccine. 2023; 41:4183-4189.

Smart, LR; Charles, M; McElhinney, KE; Dong, M; Power-Hays, A; Howard, T; Vinks, AA; Ambrose, EE; Ware, RE. Hydroxyurea pharmacokinetics and precision dosing in low-resource settings. Frontiers in Molecular Biosciences. 2023; 10:1130206.

Dong, M; Ware, RE; Dallmann, A; Vinks, AA. Hydroxyurea treatment for sickle cell anemia during pregnancy and lactation: Current evidence and knowledge gaps. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2023; 43:419-429.

Ambrose, EE; Latham, TS; Songoro, P; Charles, M; Lane, AC; Stuber, SE; Makubi, AN; Ware, RE; Smart, LR. Hydroxyurea with dose escalation for primary stroke risk reduction in children with sickle cell anaemia in Tanzania (SPHERE): an open-label, phase 2 trial. The Lancet Haematology. 2023; 10:e261-e271.

Earley, EJ; Kelly, S; Fang, F; Alencar, CS; Rodrigues, DD O W; Soares Cruz, DT; Flanagan, J; Ware, RE; Zhang, X; Gordeuk, V; Sabino, E; Custer, B; Dinardo, C; Page, GP. Genome-wide association study of early ischaemic stroke risk in Brazilian individuals with sickle cell disease implicates ADAMTS2 and CDK18 and uncovers novel loci. British Journal of Haematology. 2023; 201:343-352.

Olupot-Olupot, P; Tomlinson, G; Williams, TN; Tshilolo, L; Santos, B; Smart, LR; McElhinney, K; Howard, TA; Aygun, B; Stuber, SE; Lane, A; Latham, TS; Ware, RE. Hydroxyurea treatment is associated with lower malaria incidence in children with sickle cell anemia in sub-Saharan Africa. Blood. 2023; 141:1402-1410.

Smart, LR; Ambrose, EE; Balyorugulu, G; Songoro, P; Shabani, I; Komba, P; Charles, M; Howard, TA; McElhinney, KE; O'Hara, SM; Lane, A; Latham, TS; Makubi, AN; Ware, RE. Stroke Prevention with Hydroxyurea Enabled through Research and Education: A Phase 2 Primary Stroke Prevention Trial in Sub-Saharan Africa. Acta Haematologica. 2023; 146:95-105.

Torous, DK; Avlasevich, S; Bemis, JC; Howard, T; Ware, RE; Fung, C; Chen, Y; Sahsrabudhe, D; MacGregor, JT; Dertinger, SD. Lack of hydroxyurea-associated mutagenesis in pediatric sickle cell disease patients. Environmental and Molecular Mutagenesis. 2023; 64:167-175.

Green, NS; Zapfel, A; Nnodu, OE; Franklin, P; Tubman, VN; Chirande, L; Kiyaga, C; Chunda-Liyoka, C; Awuonda, B; Ohene-Frempong, K; Thompson, AA; Berliner, N; Coetzer, TL; Novelli, EM. The Consortium on Newborn Screening in Africa for sickle cell disease: study rationale and methodology. Blood Advances. 2022; 6:6187-6197.

Makani, J; Cavazzana, M; Gupta, K; Nnodu, O; Odame, I; Tshilolo, L; Ware, R; Luzzatto, L. Blood diseases in Africa: Redressing unjust disparities is an urgent unmet need. American Journal of Hematology. 2022; 97:1505-1506.

Dong, M; Good, A; Vinks, AA; Ware, RE; McGann, PT. Hydroxyurea Pharmacokinetics in Young Children with Sickle Cell Anemia: Results from the Therapeutic Response Evaluation and Adherence Trial (TREAT). Blood. 2022; 140:8168-8169.

Dong, M; Sadaf, A; Vinks, AA; Ware, RE; Quinn, CT. Evaluation of Dosage and Food Effect on L-Glutamine Exposure for Sickle Cell Anemia: A Population Pharmacokinetic Analysis. Blood. 2022; 140:8256-8257.

A., P; G., T; L., T; B., S; T., W; P., O; L., S; P., M; S., S; T., L; R., W. O‐01: HYDROXYUREA REDUCES THE TRANSFUSION BURDEN IN CHILDREN WITH SICKLE CELL ANEMIA IN SUB‐SAHARAN AFRICA: THE REACH EXPERIENCE. HemaSphere. 2022; 6:1.

R., N; A., C; C., B; M., G; D., D; R., W; R., O; C., J. PI‐08: HIGH DISEASE BURDEN, MORBIDITY AND MORTALITY AMONG CHILDREN WITH SICKLE CELL ANAEMIA IN UGANDA. HemaSphere. 2022; 6:13.

L., S; M., C; A., P; T., H; K., M; E., A; R., W. O‐12: BUILDING LOCAL CAPACITY FOR HYDROXYUREA PHARMACOKINETICS AND PRECISION DOSING IN LOW‐RESOURCE SETTINGS. HemaSphere. 2022; 6:7-8.

Quinn, CT; Ware, RE. New therapeutics for children with sickle cell disease: A time for celebration, caution, or both?. Pediatric Blood and Cancer. 2022; 69:e29805.

Power-Hays, A; Dandoy, CE; Lorts, A; Perentesis, JP; Unaka, N; Ware, RE; McGann, PT. US News & World Report and quality metrics: Inclusion of sickle cell disease is a matter of equity. Pediatric Blood and Cancer. 2022; 69:e29679.

Macharia, AW; Mochamah, G; Makale, J; Howard, T; Mturi, N; Olupot-Olupot, P; Färnert, A; Ware, RE; Williams, TN. Case Report: β-thalassemia major on the East African coast. Wellcome Open Research. 2022; 7:188.

Nima, MK; Mukherjee, A; Sazed, SA; Hossainey, MR H; Phru, CS; Johora, FT; Safeukui, I; Saha, A; Khan, AA; Marma, AS P; Haque, R; Khan, WA; Alam, MS; Haldar, K. Assessment of Plasmodium falciparum Artemisinin Resistance Independent of kelch13 Polymorphisms and with Escalating Malaria in Bangladesh. Editor, Bhanot P. mBio. 2022; 13:e0344421.

Quinn, CT; Ware, RE. Reproductive equity: preserve the reserve. Blood. 2022; 139:963-965.

Henrici, RC; Sautter, CL; Bond, C; Opoka, RO; Namazzi, R; Datta, D; Ware, RE; Conroy, AL; John, CC. Decreased parasite burden and altered host response in children with sickle cell anemia and severe anemia with malaria. Blood Advances. 2021; 5:4710-4720.

Rankine-Mullings, A; Reid, M; Soares, D; Taylor-Bryan, C; Wisdom-Phipps, M; Aldred, K; Latham, T; Schultz, WH; Knight-Madden, J; Badaloo, A; Lane, A; Adams, RJ; Ware, RE. Hydroxycarbamide treatment reduces transcranial Doppler velocity in the absence of transfusion support in children with sickle cell anaemia, elevated transcranial Doppler velocity, and cerebral vasculopathy: the EXTEND trial. British Journal of Haematology. 2021; 195:612-620.

Quinn, CT; Ware, RE. Increased oxygen affinity: to have and to hold. Blood. 2021; 138:1094-1095.

Sadaf, A; Ware, RE. Microscope diagnosis of MYH9-related thrombocytopenia. Blood. 2021; 138:1000.

Sadaf, A; Quinn, CT; Korpik, JB; Pfeiffer, A; Reynaud, M; Niss, O; Malik, P; Ware, RE; Kalfa, TA; McGann, PT. Rapid and automated quantitation of dense red blood cells: A robust biomarker of hydroxyurea treatment response. Blood Cells, Molecules, and Diseases. 2021; 90:102576.

Pecker, LH; Sharma, D; Nero, A; Paidas, MJ; Ware, RE; James, AH; Smith-Whitley, K. Knowledge gaps in reproductive and sexual health in girls and women with sickle cell disease. British Journal of Haematology. 2021; 194:970-979.

Hernandez, AG; Kiyaga, C; Howard, TA; Ssewanyana, I; Ndeezi, G; Aceng, JR; Ware, RE. Operational analysis of the national sickle cell screening programme in the Republic of Uganda. African Journal of Laboratory Medicine. 2021; 10:1303.

Quinn, CT; Niss, O; Dong, M; Pfeiffer, A; Korpik, J; Reynaud, M; Bonar, H; Kalfa, TA; Smart, LR; Malik, P; Ware, RE; Vinks, AA; McGann, PT. Early initiation of hydroxyurea (hydroxycarbamide) using individualised, pharmacokinetics-guided dosing can produce sustained and nearly pancellular expression of fetal haemoglobin in children with sickle cell anaemia. British Journal of Haematology. 2021; 194:617-625.

Davis, G; York, AJ; Bacon, WC; Lin, SC; McNeal, MM; Yarawsky, AE; Maciag, JJ; Miller, JL C; Locker, KC S; Bailey, M; Jordan, MB; Herr, AB; Hildeman, DA; Molkentin, JD. Seroprevalence of SARS-CoV-2 infection in Cincinnati Ohio USA from August to December 2020. Editor, Kumar B. PloS one. 2021; 16:e0254667.

Smart, LR; Ware, RE. Newborn screening for sickle cell disease in sub-Saharan Africa: Is the glass half-full yet?. Pediatric Blood and Cancer. 2021; 68:e29137.

Ware, RE; Dertinger, SD. Absence of hydroxyurea-induced mutational effects supports higher utilisation for the treatment of sickle cell anaemia. British Journal of Haematology. 2021; 194:252-266.

Tegha, G; Topazian, HM; Kamthunzi, P; Howard, T; Tembo, Z; Mvalo, T; Chome, N; Kumwenda, W; Mkochi, T; Hernandez, A; Ataga, KI; Hoffman, IF; Ware, RE. Prospective Newborn Screening for Sickle Cell Disease and Other Inherited Blood Disorders in Central Malawi. International Journal of Public Health. 2021; 66:629338.

Maitland, K; Kiguli, S; Olupot-Olupot, P; Opoka, RO; Chimalizeni, Y; Alaroker, F; Uyoga, S; Kyeyune-Byabazaire, D; M’baya, B; Bates, I; Lyimo, M; Anani, L; Ofori, SO; Engoru, C. Transfusion management of severe anaemia in African children: a consensus algorithm. British Journal of Haematology. 2021; 193:1247-1259.

Karkoska, K; Todd, K; Niss, O; Clapp, K; Fenchel, L; Kalfa, TA; Malik, P; Quinn, CT; Ware, RE; McGann, PT. Implementation of near-universal hydroxyurea uptake among children with sickle cell anemia: A single-center experience. Pediatric Blood and Cancer. 2021; 68:e29008.

Hood, AM; Strong, H; Nwankwo, C; Johnson, Y; Peugh, J; Mara, CA; Shook, LM; Brinkman, WB; Real, FJ; Klein, MD; Treadwell, M; Quinn, CT; Ware, RE; Crosby, LE. Engaging Caregivers and Providers of Children With Sickle Cell Anemia in Shared Decision Making for Hydroxyurea: Protocol for a Multicenter Randomized Controlled Trial. JMIR Research Protocols. 2021; 10:e27650.

Boucher, AA; Dong, M; Vinks, AA; Marahatta, A; Howard, TA; Ware, RE; Nathan, JD; Abu-El-Haija, M; Luchtman-Jones, L. Hydroxyurea Pharmacokinetics in Pediatric Patients After Total Pancreatectomy With Islet Autotransplantation. The Journal of Clinical Pharmacology. 2021; 61:547-554.

Sadaf, A; Seu, KG; Thaman, E; Fessler, R; Konstantinidis, DG; Bonar, HA; Korpik, J; Ware, RE; McGann, PT; Quinn, CT; Kalfa, TA. Automated Oxygen Gradient Ektacytometry: A Novel Biomarker in Sickle Cell Anemia. Frontiers in Physiology. 2021; 12:636609.

Smart, L; Ambrose, EE; Charles, M; BScHLS, ; Perez-Plazola, M; Shabani, I; Komba, P; Songoro, P; Tyburski, E; Lam, W; Ware, RE; McGann, PT. Bedside Expedited Testing for Anemia in Tanzania: the BETA Study. Pediatrics. 2021; 147:230-231.

Ware, RE; Dertinger, SD. There's safety in numbers. Blood. 2021; 137:729-731.

Cazelles, R; Shukla, RP; Ware, RE; Vinks, AA; Ben-Yoav, H. Electrochemical Determination of Hydroxyurea in a Complex Biological Matrix Using MoS2-Modified Electrodes and Chemometrics. Biomedicines. 2021; 9:6.

Hernandez, AG; Kiyaga, C; Howard, TA; Ssewanyana, I; Ndeezi, G; Aceng, JR; Ware, RE. Trends in sickle cell trait and disease screening in the Republic of Uganda, 2014-2019. Tropical Medicine and International Health. 2021; 26:23-32.

Perez-Plazola, MS; Tyburski, EA; Smart, LR; Howard, TA; Pfeiffer, A; Ware, RE; Lam, WA; McGann, PT. AnemoCheck-LRS: an optimized, color-based point-of-care test to identify severe anemia in limited-resource settings. BMC Medicine. 2020; 18:337.

Ambrose, EE; Smart, LR; Charles, M; Hernandez, AG; Latham, T; Hokororo, A; Beyanga, M; Howard, TA; Kamugisha, E; McElhinney, KE; Tebuka, E; Ware, RE. Surveillance for sickle cell disease, United Republic of Tanzania. Bulletin of the World Health Organization. 2020; 98:859-868.

Marahatta, A; Flanagan, JM; Howard, TA; Mortier, N; Schultz, W; McElhinney, KL; Tshilolo, L; Williams, TN; Olupot-Olupot, P; Santos, B; Tomlinson, GA; Latham, T; Stuber, SE; Ware, RE. Genetic Variants That Influence Fetal Hemoglobin Expression from Hydroxyurea Treatment. Blood. 2020; 136:8-9.

Sadaf, A; Quinn, CT; Korpik, JB; Pfeiffer, A; Reynaud, M; Niss, O; Malik, P; Ware, RE; Kalfa, TA; McGann, PT. Rapid and Automated Quantitation of Dense Red Blood Cells: A Robust Biomarker of Therapeutic Response to Early Initiation of Hydroxyurea in Young Children with Sickle Cell Anemia. Blood. 2020; 136:16-17.

Marahatta, A; Howard, TA; Stuber, SE; McElhinney, KL; Tshilolo, L; Williams, TN; Olupot-Olupot, P; Santos, B; John, CC; Opoka, R; Baker, J; Latham, T; Flanagan, JM; Ware, RE. Novel Genetic Loci That Influence Fetal Hemoglobin Expression in Children with Sickle Cell Anemia. Blood. 2020; 136:33-34.

George, A; Dinu, B; Estrada, N; Minard, CG; Hurwitz, R; Mahoney, DH; Yates, AM; Vaughan, M; Carmouche, A; Airewele, G; Kirk, SE; Fasipe, T; Uwaezuoke, P; Ware, RE. Novel dose escalation to predict treatment with hydroxyurea (NDEPTH): A randomized controlled trial of a dose-prediction equation to determine maximum tolerated dose of hydroxyurea in pediatric sickle cell disease. American Journal of Hematology. 2020; 95:E242-E244.

Ware, RE; Marahatta, A; Ware, JL; McElhinney, K; Dong, M; Vinks, AA. Hydroxyurea Exposure in Lactation: a Pharmacokinetics Study (HELPS). The Journal of Pediatrics. 2020; 222:236-239.

Jr, TB L; Lloyd-Puryear, MA; Ohene-Frempong, K; Ware, RE; Padilla, CD; Ambrose, EE; Barkat, A; Ghazal, H; Kiyaga, C; Mvalo, T; Yusuf, C; Zarbalian, G; Watson, MS; Newborn, FP A W. Empowering newborn screening programs in African countries through establishment of an international collaborative effort. Journal of Community Genetics. 2020; 11:253-268.

Macharia, AW; Mochamah, G; Uyoga, S; Ndila, CM; Nyutu, G; Tendwa, M; Nyatichi, E; Makale, J; Ware, RE; Williams, TN. β-Thalassemia pathogenic variants in a cohort of children from the East African coast. Molecular Genetics and Genomic Medicine. 2020; 8:e1294.

John, CC; Opoka, RO; Latham, TS; Hume, HA; Nabaggala, C; Kasirye, P; Ndugwa, CM; Lane, A; Ware, RE. Hydroxyurea Dose Escalation for Sickle Cell Anemia in Sub-Saharan Africa. The New England Journal of Medicine. 2020; 382:2524-2533.

Power-Hays, A; Ware, RE. Effective use of hydroxyurea for sickle cell anemia in low-resource countries. Current Opinion in Hematology. 2020; 27:172-180.

Carman, AS; Sautter, C; Anyanwu, JN; Ssemata, AS; Opoka, RO; Ware, RE; Rujumba, J; John, CC. Perceived benefits and risks of participation in a clinical trial for Ugandan children with sickle cell anemia. Pediatric Blood and Cancer. 2020; 67:e27830.

Hood, AM; McTate, EA; Joffe, NE; Crosby, LE. Sickle Cell Disease. In: Orkin SH; Nathan DG; Ginsburg D; Look AT; Fisher DE; Lux SE, Ed. Clinical Handbook of Psychological Consultation in Pediatric Medical Settings. Philadelphia, PA: Springer Nature; 2020.